Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results.
Merck & Co has lowered its full-year revenue and earnings estimates because of the impact of COVID-19 on its business, which is focused on products administered in hospitals. <
The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”
China’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing of its potential Alzheimer’s drug.
Gilead's COVID-19 drug remdesivir seemingly failed to produce an effect according to results of a Chinese clinical trial posted inadvertently on the World Health Organizatio